
ENDRA Life Sciences NDRA
$ 5.29
-3.78%
Quarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Accounts Receivables 2011-2025 | NDRA
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 6.85 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.85 K | 6.85 K | 6.85 K |
Quarterly Accounts Receivables ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.3 K | 11.8 K | 11.8 K | 6.85 K | 6.85 K | 6.85 K | 6.85 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.3 K | 6.85 K | 9.03 K |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 15.82 | 0.44 % | $ 170 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.55 | -4.63 % | $ 1.97 M | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 12.14 | 2.1 % | $ 344 M | ||
|
DexCom
DXCM
|
974 M | $ 65.83 | -1.69 % | $ 25.4 B | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 39.06 | 1.11 % | $ 1.08 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Exact Sciences Corporation
EXAS
|
249 M | $ 101.64 | 0.14 % | $ 18.8 B | ||
|
Danaher Corporation
DHR
|
3.54 B | $ 227.72 | 0.54 % | $ 166 B | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 27.0 | -0.52 % | $ 816 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 19.98 | -2.82 % | $ 1.07 B | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
173 K | $ 3.3 | -7.82 % | $ 105 K | ||
|
Co-Diagnostics
CODX
|
304 K | $ 0.29 | -14.47 % | $ 8.51 M | ||
|
IQVIA Holdings
IQV
|
3.2 B | $ 222.75 | 0.24 % | $ 40.4 B | ||
|
Guardant Health
GH
|
110 M | $ 103.7 | 1.6 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
735 M | $ 134.4 | -0.35 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
721 M | $ 197.62 | 2.4 % | $ 10.2 B | ||
|
Quotient Limited
QTNT
|
5.32 M | - | -11.32 % | $ 1.1 M | ||
|
Mettler-Toledo International
MTD
|
687 M | $ 1 410.02 | 1.15 % | $ 29.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 183.96 | 0.79 % | $ 20.4 B | ||
|
NeoGenomics
NEO
|
151 M | $ 12.03 | 1.48 % | $ 1.52 B | ||
|
Neogen Corporation
NEOG
|
153 M | $ 6.85 | -0.22 % | $ 1.49 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 7.63 | -2.8 % | $ 989 M | ||
|
Myriad Genetics
MYGN
|
121 M | $ 7.04 | -2.36 % | $ 638 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 262.89 | -0.48 % | $ 22.1 B | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 184.38 | -1.18 % | $ 15.2 B | ||
|
IDEXX Laboratories
IDXX
|
474 M | $ 698.77 | -0.77 % | $ 57.6 B | ||
|
Lantheus Holdings
LNTH
|
321 M | $ 66.4 | -0.33 % | $ 4.59 B | ||
|
Agilent Technologies
A
|
1.17 B | $ 140.3 | 0.46 % | $ 42.7 B | ||
|
Biomerica
BMRA
|
731 K | $ 2.48 | -2.65 % | $ 5.7 M | ||
|
Bioventus
BVS
|
123 M | $ 7.49 | -0.86 % | $ 469 M | ||
|
Pacific Biosciences of California
PACB
|
36.6 M | $ 2.13 | 0.24 % | $ 540 M | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K |